TABLE 2.

List of DPP-4 inhibitors (Kumar et al., 2021).

S.No.	DPP-4 inhibitors	Name		Year of approval
1	Approved Augeri et al. (2005), Hulin et al. (2005), Del Prato (2007), Thornberry and Weber (2007), Yoshida et al. (2012), Burness (2015), Nishio et al. (2015), Grimshaw et al. (2016), Kim et al. (2016), Tan and Hu (2016), Shiheido-Watanabe et al. (2021)	i.	Sitagliptin phosphate monohydrate	2006 (United States)
		ii.	Vildagliptin	2007 (European Union)
		iii.	Saxagliptin hydrochloride	2009 (United States)
		iv.	Alogliptin Benzoate	2010 (Japan)
		v.	Linagliptin	2011 (United States)
		vi.	Gemigliptin L-tartrate sesquihydrate	2012 (South Korea)
		vii.	Anagliptin	2012 (Japan)
		viii.	Tenegliptin Hydrobromide Hydrate	2012 (Japan)
		ix.	Denagliptin tosilate	2014 (United States)
		x.	Omarigliptin	2015 (Japan)
		xi.	Evogliptin Hydrochloride	2015 (South Korea)
		xii.	Trelagliptin Succinate	2015 (Japan)
2	In phase 3 clinical trials	i.	Fotagliptin Benzoate	NA
		ii.	CPL 2009–0031	NA
		iii.	DBPR-108	NA
3	In phase 1 clinical trials	i.	DC291407	NA
		ii.	Augliptin Hydrochloride	NA
		iii.	Yogliptin	NA
		iv.	HD118	NA
		v.	ARI-2243	NA
		vi.	Cetagliptin phosphate	NA
		vii.	PBL-1427	NA
		viii.	HSK-7653	NA
4	In phase 2 clinical trials	i.	Besigliptin Tosilate	NA
		ii.	Imigliptin Hydrochloride	NA
5	NDA filed	i.	Gosogliptin Hydrochloride	NA
		ii.	Retagliptin Phosphate	NA